PubMed
Delta sleep-inducing peptide (DSIP): A review
Graf et al., 1986
Neurological & CognitiveResearch OnlyB
DSIP
Delta Sleep-Inducing Peptide
Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated in 1977 from thalamic perfusate of sleeping rabbits by Monnier et al. that induced slow-wave (delta) sleep when infused. Subsequent research has explored roles in pain modulation, stress response, temperature regulation, and antioxidant effects. Clinical evidence is limited and inconsistent; mechanism remains poorly characterized. Research only.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 6
- Research grade
- B
- Experience
- 56
- Activity
- 62
Overall check-ins
Trackers & reports
Overview
About DSIP
Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated in 1977 from thalamic perfusate of sleeping rabbits by Monnier et al. that induced slow-wave (delta) sleep when infused. Subsequent research has explored roles in pain modulation, stress response, temperature regulation, and antioxidant effects. Clinical evidence is limited and inconsistent; mechanism remains poorly characterized. Research only.
- Category
- Neurological & Cognitive
- Regulatory status
- Research Only
- Also known as
- Delta Sleep-Inducing Peptide
- Self-reports
- 49
Community
What 49 users report
49 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Sleep
182
Mood
182
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
177
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 200–400 mcg
Reports span 25–600 mcg
25–50
5
50–100
2
100–200
38
200–400
131
400–600
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 85% said they felt similar to their last entry, 15% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 62 days · Based on 33 repeat reporters
Research
Cited research (5)
Source
PubMed
DSIP and stress tolerance in rats
Sudakov et al., 1988
ClinicalTrials.gov
DSIP studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Delta sleep-inducing peptide
Pollard et al., 2001
PubMed
Delta-sleep-inducing peptide (DSIP): a review
Graf et al., 1984
Tools
Explore more
Explore
More ways to learn about DSIP from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about DSIP?
This page summarizes 49 anonymized self-reports from PeptIQ users who track DSIP, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for DSIP?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for DSIP?
5 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is DSIP safe to use?
This wiki does not assess safety or recommend use. DSIP is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of DSIP?
Research, primarily in animal models, suggests DSIP may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of DSIP?
DSIP is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified DSIP as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of DSIP?
The safety and effectiveness of DSIP have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on DSIP?
While there are over 200 published studies on DSIP, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source